The data indicated that the serum GPX4 level in patients in the HBV+-HCC group was higher than that in the CHB group; also, both the HBV+-HCC and CHB groups had higher serum GPX4 levels compared with the HCs (Figure 6(e)). The gene discussed is GPX4; the disease is hepatocellular carcinoma.